Sofosbuvir 400 mg and daclatasvir 60 mg

DRUG2 trials

Sponsors

Tehran University of Medical Sciences, ANRS, Emerging Infectious Diseases

Conditions

Chronic Renal FailureDrug UseHepatitis CHepatitis C, ChronicViral Hepatitis C

Phase 4

Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir

CompletedNCT03063879

Tehran University of Medical SciencesChronic Renal Failure, Hepatitis C, Chronic

Start: 2017-04-01End: 2019-02-01Updated: 2019-09-30

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)

CompletedNCT03537196

ANRS, Emerging Infectious DiseasesDrug Use, Hepatitis C, Viral Hepatitis C

Start: 2018-11-13End: 2022-12-30Updated: 2023-10-26

Related Papers

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam.

2025-11-01

Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam–hepatitis C)

BMJ Open2020-11-0117 citations

The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment

Journal of Gastroenterology and Hepatology2020-01-2925 citations